Literature DB >> 35497670

Primary Myelofibrosis in the Prefibrotic Stage Presenting as Portal, Splenic, and Superior Mesenteric Vein Thrombosis: A Case Report and Review of the Literature.

Emanuel Dias1, Rodrigo Liberal1, Pedro Costa-Moreira1, Fernando Príncipe2, Elsa Fonseca3, Guilherme Macedo1.   

Abstract

Introduction: Myeloproliferative neoplasms are the most common cause of splanchnic vein thrombosis in the absence of cirrhosis or nearby malignancy. Case Presentation: A 31-year-old male presented to the emergency department with epigastric pain associated with mild thrombocytosis and elevated levels of aminotransferases, lactate dehydrogenase, and C-reactive protein. Contrast-enhanced abdominal computed tomography revealed splanchnic venous thrombosis that involved the portal, splenic, and superior mesenteric veins, without signs of chronic liver disease. Anticoagulation with warfarin was immediately started. Diagnostic work-up was remarkable for the presence of the JAK2 V617T mutation and hypercellular bone marrow, with increased myeloid cells and atypical megakaryocytes, consistent with primary myelofibrosis in a prefibrotic stage. No other hypercoagulable conditions were identified. Discussion: We present a rare case of primary myelofibrosis in the prefibrotic stage presenting as portal-splenic-superior mesenteric vein thrombosis. This demonstrates that extensive splanchnic vein thrombosis may be the onset manifestation of myeloproliferative neoplasms, even in early stages and in the absence of concomitant hypercoagulable conditions. The presence of the JAK2 mutation is an important prothrombotic risk factor that can, per se, contribute to large venous thrombosis.
Copyright © 2021 by S. Karger AG, Basel.

Entities:  

Keywords:  Myeloproliferative neoplasm; Portal vein thrombosis; Primary myelofibrosis; Splanchnic vein thrombosis

Year:  2021        PMID: 35497670      PMCID: PMC8995663          DOI: 10.1159/000514658

Source DB:  PubMed          Journal:  GE Port J Gastroenterol        ISSN: 2387-1954


  23 in total

1.  Splenic-portal- mesenteric thrombosis with splenic infarction as first presentation of essential thrombocytosis.

Authors:  Julio Maria Fonseca Chebli; Pedro Duarte Gaburri; Aécio Flávio Meirelles de Souza; Guilherme Eduardo Gonçalves Felga; Cecília Ganimi Forn; Janine Radd Ferreira Pinto
Journal:  J Clin Gastroenterol       Date:  2004-07       Impact factor: 3.062

2.  The epidemiology and clinical features of portal vein thrombosis: a multicentre study.

Authors:  R Rajani; E Björnsson; A Bergquist; A Danielsson; A Gustavsson; O Grip; T Melin; P Sangfelt; S Wallerstedt; S Almer
Journal:  Aliment Pharmacol Ther       Date:  2010-09-15       Impact factor: 8.171

3.  How I Manage Thrombotic/Thromboembolic Complications in Myeloproliferative Neoplasms.

Authors:  Steffen Koschmieder
Journal:  Hamostaseologie       Date:  2020-02-12       Impact factor: 1.778

4.  Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases.

Authors:  Emanuela Sant'Antonio; Paola Guglielmelli; Lisa Pieri; Massimo Primignani; Maria Luigia Randi; Claudia Santarossa; Elisa Rumi; Francisco Cervantes; Federica Delaini; Alessandra Carobbio; Silvia Betti; Elena Rossi; Noa Lavi; Claire N Harrison; Natalia Curto-Garcia; Heinz Gisslinger; Bettina Gisslinger; Giorgina Specchia; Alessandra Ricco; Nicola Vianelli; Nicola Polverelli; Maya Koren-Michowitz; Marco Ruggeri; Francois Girodon; Martin Ellis; Alessandra Iurlo; Francesco Mannelli; Lara Mannelli; Benedetta Sordi; Giuseppe Gaetano Loscocco; Mario Cazzola; Valerio De Stefano; Tiziano Barbui; Ayalew Tefferi; Alessandro Maria Vannucchi
Journal:  Am J Hematol       Date:  2019-11-29       Impact factor: 10.047

5.  [Mesenteric venous thrombosis. A retrospective study of 23 cases].

Authors:  Virginie Rieu; Marc Ruivard; Armand Abergel; Denis Pezet; Alain-Charles Fouilhoux; Olivier Tournilhac; Pierre Philippe
Journal:  Ann Med Interne (Paris)       Date:  2003-05

6.  [Mesenteric and splenic vein thrombosis in a female patient with essential thrombocytosis and activated protein C resistance].

Authors:  Dragomir Marisavljević; Ivo Elezović; Dragoljub Bilanović; Natasa Petrović; Mirjana Janjić; Dijana Sefer
Journal:  Vojnosanit Pregl       Date:  2003 Mar-Apr       Impact factor: 0.168

7.  Splanchnic vein thrombosis as a first manifestation of Primary myelofibrosis

Authors:  Gregorio Campos-Cabrera; Virginia Campos-Cabrera; Salvador Campos-Cabrera; José-Luis Campos-Villagómez; Alejandra Romero-González
Journal:  Gac Med Mex       Date:  2017       Impact factor: 0.302

Review 8.  The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion.

Authors:  Tiziano Barbui; Jürgen Thiele; Heinz Gisslinger; Hans Michael Kvasnicka; Alessandro M Vannucchi; Paola Guglielmelli; Attilio Orazi; Ayalew Tefferi
Journal:  Blood Cancer J       Date:  2018-02-09       Impact factor: 11.037

Review 9.  Use of Interferon Alfa in the Treatment of Myeloproliferative Neoplasms: Perspectives and Review of the Literature.

Authors:  Joan How; Gabriela Hobbs
Journal:  Cancers (Basel)       Date:  2020-07-18       Impact factor: 6.639

10.  Addressing and proposing solutions for unmet clinical needs in the management of myeloproliferative neoplasm-associated thrombosis: A consensus-based position paper.

Authors:  Tiziano Barbui; Valerio De Stefano; Anna Falanga; Guido Finazzi; Ida Martinelli; Francesco Rodeghiero; Alessandro M Vannucchi; Giovanni Barosi
Journal:  Blood Cancer J       Date:  2019-08-08       Impact factor: 11.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.